Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades-Reference-Cited by-同舟云学术

Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades

Published:2016-08-12 Issue:10 Volume:5 Page:e1219826
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Das Asha M.¹,Pescatori Mario¹,Vermeulen Cindy E.¹,Rens Joost A. P.¹,Seynhaeve Ann L. B.¹,Koning Gerben A.¹,Eggermont Alexander M. M.¹²,ten Hagen Timo L. M.¹

Affiliation:

1. Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands

2. Gustave Roussy Cancer Campus Grand Paris, Villejuif, France

Funder

Stichting Erasmus Heelkundig Kankeronderzoek

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/2162402X.2016.1219826

Reference48 articles.

1. Cutaneous melanoma

2. Cutaneous Malignant Melanoma

3. Systemic treatment of metastatic melanoma: New approaches

4. Final Version of 2009 AJCC Melanoma Staging and Classification

5. Melanoma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance;Cells;2021-04-09

2. Euscaphic acid and Tormentic acid protect vascular endothelial cells against hypoxia-induced apoptosis via PI3K/AKT or ERK 1/2 signaling pathway;Life Sciences;2020-07

3. Kaji-Ichigoside F1 and Rosamultin Protect Vascular Endothelial Cells against Hypoxia-Induced Apoptosis via the PI3K/AKT or ERK1/2 Signaling Pathway;Oxidative Medicine and Cellular Longevity;2020-03-30

4. CREPT Promotes Melanoma Progression Through Accelerated Proliferation and Enhanced Migration by RhoA-Mediated Actin Filaments and Focal Adhesion Formation;Cancers;2019-12-20

5. Tussilagone Suppresses Angiogenesis by Inhibiting the VEGFR2 Signaling Pathway;Frontiers in Pharmacology;2019-07-05